Details for New Drug Application (NDA): 212219
✉ Email this page to a colleague
NDA 212219 describes DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), which is a drug marketed by Ayana Pharma Ltd, Baxter Hlthcare Corp, Dr Reddys, Lupin, Sun Pharm, and Zydus Lifesciences, and is included in six NDAs. It is available from seven suppliers. Additional details are available on the DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) profile page.
The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
The generic ingredient in DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) is doxorubicin hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the doxorubicin hydrochloride profile page.
Summary for 212219
| Tradename: | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) |
| Applicant: | Baxter Hlthcare Corp |
| Ingredient: | doxorubicin hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 212219
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE, LIPOSOMAL;INJECTION | Strength | 20MG/10ML (2MG/ML) | ||||
| Approval Date: | Oct 19, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE, LIPOSOMAL;INJECTION | Strength | 50MG/25ML (2MG/ML) | ||||
| Approval Date: | Oct 19, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
